MedTrace Logo

Safety Evaluation of Seraph® 100 to Reduce Bacteremia in Patients on Hemodialysis

NCT02914132 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-08-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) is safe in the treatment of dialysis patients with bacteremia.

Conditions

Interventions

DEVICE

Seraph 100 Filter

Treatment of renal replacement therapy patients with bacteremia.

Sponsors & Collaborators

  • ExThera Medical Corporation

    lead INDUSTRY

Principal Investigators

  • Jan T Kielstein, MD,FASN,FERA · Academic Teaching Hospital Braunschweig

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-06-07
Completion
2018-06-07

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02914132 on ClinicalTrials.gov